Telo Genomics P/CF

Que fait Telo Genomics ? Telo Genomics Corp, a biotechnology company based in Toronto, Ontario, focuses on developing and commercializing technological products aimed at personalizing treatment plans for patients with specific conditions. The company, which went public on February 15, 2012, is engaged in the development of predictive diagnostic tools. Its lead product, TeloView SMM, is a high-complexity molecular assay designed for clinical use. TeloView SMM provides physicians with information to guide treatment decisions for patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, the assay identifies high-risk patients who may benefit from earlier intervention and distinguishes them from low-risk patients with a more stable disease course who do not require immediate treatment. Telo Genomics Corp operates through its wholly owned subsidiary, Telo Genomics Holdings Corp., which is developing diagnostic and prognostic products for diseases exhibiting genomic instability. The company's website is www.telodx.com. Telo Genomics Corp is listed on the Canadian market under the ticker TELO.V with ISIN CA87975M2085. Telo Genomics est l'une des entreprises les plus populaires sur Eulerpool.